5 March 2015 Low level laser (light) therapy and photobiomodulation: the path forward
Author Affiliations +
Proceedings Volume 9309, Mechanisms for Low-Light Therapy X; 930902 (2015) https://doi.org/10.1117/12.2084049
Event: SPIE BiOS, 2015, San Francisco, California, United States
Abstract
Low level laser (light) therapy (LLLT) also known as photobiomodulation (PBM) therapy has been practiced for almost fifty years, and hundreds of positive clinical trials and thousands of laboratory studies have been published. Despite these impressive accomplishments LLLT has still not reached the stage of acceptance by mainstream medicine. The reasons for this were discussed at a recent Optical Society of America (OSA) Incubator meeting in Washington DC in 2014. Uncertainty about mechanisms was highlighted, and this paper will describe the current thinking. To drive LLLT towards mainstream medicine, we need better guidelines with standardized protocols and consistent parameters. Studies should be published in higher impact scientific and medical journals. Companies should avoid false promises and deceptive marketing, and physicians should receive a clearly defined return on investment with insurance reimbursement.
© (2015) COPYRIGHT Society of Photo-Optical Instrumentation Engineers (SPIE). Downloading of the abstract is permitted for personal use only.
Michael R. Hamblin, Michael R. Hamblin, Marcelo Victor Pires de Sousa, Marcelo Victor Pires de Sousa, Praveen R. Arany, Praveen R. Arany, James D. Carroll, James D. Carroll, Donald Patthoff, Donald Patthoff, } "Low level laser (light) therapy and photobiomodulation: the path forward", Proc. SPIE 9309, Mechanisms for Low-Light Therapy X, 930902 (5 March 2015); doi: 10.1117/12.2084049; https://doi.org/10.1117/12.2084049
PROCEEDINGS
11 PAGES


SHARE
Back to Top